» Articles » PMID: 30020195

Long-term Relative Survival from Melanoma in Germany 1997-2013

Overview
Journal Melanoma Res
Specialty Oncology
Date 2018 Jul 19
PMID 30020195
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Up-to-date melanoma relative survival (RS) estimates and trend analysis facilitate close monitoring of melanoma patients' prognosis. This study aimed to provide recent 5-year and 10-year RS from melanoma, stratified by prognostic factors, and identify latest survival trends. Data from 12 German cancer registries were analysed. We included patients with primary cutaneous malignant melanoma (ICD-10: C43.X) diagnosed in 1997-2013 who were at least 15 years old. Five-year and 10-year RS were estimated by period analysis. For 10-year RS analyses, we excluded patients who were 75 years of age or older. Analyses were stratified by sex, age, histology, tumour stage, and body site. We included 82 901 patients, of whom 51% were women. The median age at diagnosis was 62 years. Five-year and 10-year RS in 2007-2013 were 92.4 and 90.8%, respectively. RS was higher in women. The prognosis worsened with older age and higher stage. In superficial spreading melanoma and lentigo maligna melanoma, RS was high; it was lower in nodular, acral lentiginous and 'other' melanoma. RS was the highest for melanoma on the arms; RS for melanoma on unknown or overlapping sites of the skin was the lowest. Five-year and 10-year RS increased significantly from 2005-2007 and 2008-2010 to 2011-2013, by 3.5 and 3.3 percentage points, respectively. For melanoma of 'other' histology, 5-year and 10-year RS increased significantly. Ten-year RS also increased significantly in men with superficial spreading melanoma and T4 melanoma, and in women with T3 melanoma. Melanoma RS improved, especially in certain subgroups. The reasons for improvements need to be investigated further.

Citing Articles

Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients.

Lo S, Williams G, Cust A, Varey A, Md S, Chng S J Natl Cancer Inst. 2024; 117(1):152-156.

PMID: 39245462 PMC: 11717414. DOI: 10.1093/jnci/djae198.


Development and validation of two online dynamic nomograms for patients with non-distant metastatic cutaneous melanoma based on surgical approaches.

Wang S, Chen Y, Sun J, Mo R, Tan Q Cancer Med. 2023; 12(18):18479-18490.

PMID: 37592896 PMC: 10557963. DOI: 10.1002/cam4.6448.


Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches.

Mitusova K, Peltek O, Karpov T, Muslimov A, Zyuzin M, Timin A J Nanobiotechnology. 2022; 20(1):412.

PMID: 36109754 PMC: 9479308. DOI: 10.1186/s12951-022-01610-7.


PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.

Yang G, Liu S, Maghsoudloo M, Shasaltaneh M, Jabbarzadeh Kaboli P, Zhang C Sci Rep. 2021; 11(1):6056.

PMID: 33723350 PMC: 7961027. DOI: 10.1038/s41598-021-85595-7.


The role of vascular mimicry as a biomarker in malignant melanoma: a systematic review and meta-analysis.

Zhang Z, Imani S, Shasaltaneh M, Hosseinifard H, Zou L, Fan Y BMC Cancer. 2019; 19(1):1134.

PMID: 31752759 PMC: 6873453. DOI: 10.1186/s12885-019-6350-5.